(68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer

We aim to investigate the pharmacokinetics and distribution of the recently clinically introduced radioligand (68)Ga-PSMA-11 in men with recurrent prostate cancer (PC) by means of dynamic and whole-body PET/CT. The correlation between PSA levels and (68)Ga-PSMA-11 PET parameters is also investigated...

Full description

Saved in:
Bibliographic Details
Published in:European journal of nuclear medicine and molecular imaging 2016-07, Vol.43 (7), p.1288
Main Authors: Sachpekidis, C, Eder, M, Kopka, K, Mier, W, Hadaschik, B A, Haberkorn, U, Dimitrakopoulou-Strauss, A
Format: Article
Language:English
Subjects:
Aged
Antigens, Surface - metabolism
Edetic Acid - analogs & derivatives
Glutamate Carboxypeptidase II - metabolism
Humans
Male
Middle Aged
Oligopeptides
Pelvis - diagnostic imaging
Positron Emission Tomography Computed Tomography
Prostatic Neoplasms - diagnostic imaging
Prostatic Neoplasms - metabolism
Recurrence
Whole Body Imaging
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We aim to investigate the pharmacokinetics and distribution of the recently clinically introduced radioligand (68)Ga-PSMA-11 in men with recurrent prostate cancer (PC) by means of dynamic and whole-body PET/CT. The correlation between PSA levels and (68)Ga-PSMA-11 PET parameters is also investigated. 31 patients with biochemical failure after primary PC treatment with curative intent (median age 71.0 years) were enrolled in the analysis. The median PSA value was 2.0 ng/mL (range = 0.1 - 130.0 ng/mL) and the median Gleason score was 7 (range = 5 - 9). 8/31 (25.8 %) of the included patients had a PSA value 
ISSN:1619-7089
DOI:10.1007/s00259-015-3302-4